Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective
Update: 2025-10-02
Description
The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:
-
Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology
-
Long-term safety of topical therapies for chronic AD
-
Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial
-
Shifting the paradigm of topical AD care across patient populations
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
